top of page

Available Trials 

Metastatic
Colorectal Cancer 

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

More Information

Advanced/Metastatic
Non-Small Cell Lung Cancer

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

More Information

Multiple Myeloma

This single-arm, prospective observational study aims to assess the incidence of and risk factors for severe (Grades 3 to 4) and fatal (Grade 5) infusion-related reactions (IRRs) in participants treated with intravenous (IV) or subcutaneous (SC) daratumumab for the treatment of multiple myeloma (MM) in the clinical practice setting (in accordance with approved local labelling) and to characterize potential risk factors.

More Information

Early Stage 
Breast Cancer or
Non-small cell lung cancer

Thea aim of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in stage IB to IIIB NSCLC and stage I to III breast cancer patients

More Information

Advanced/Metastatic 
Non-Small Cell Lung Cancer 

A Phase 2 trial of adagrasib monotherapy in combination with pembrolizumab and a Phase 3 trial of adagrasib in combination with pembrolizumab verse pembrolizumab in patients with advanced non-small cell lung cancer with KRAS G12C mutations

More Information

Solid Tumors harboring 

BRAF fusions

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations 

More Information

Prostate Cancer
HHR Mutations

IRONMAN Registration sub-study; PRODIGY: Observational study to describe effectiveness in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations (BARD1, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L)

More Information

CNS Tumors harboring 
BRAF V600E

​A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations 

More Information

Solid Tumors
EGFR and FGFR2 Mutations

An open-label, first-in-human, dose-escalation and dose-expansion, phase 1/2 study of BB1-355 and BB1-355 in combination with select targeted therapies in subjects with locally advanced or metastatic solid tumors with oncogene amplifications

More Information

CNS Tumors harboring 
BRAF V600E

​A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations 

More Information

Solid Tumors
EGFR and FGFR2 Mutations

An open-label, first-in-human, dose-escalation and dose-expansion, phase 1/2 study of BB1-355 and BB1-355 in combination with select targeted therapies in subjects with locally advanced or metastatic solid tumors with oncogene amplifications

More Information

CNS Tumors harboring 
BRAF V600E

​A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations 

More Information

Hormone Receptor Positive
Breast Cancer

Saruparib (AZD5305) plus Camizestrant compared with CDK4/6 inhibitor plus endocrine therapy or plus camizestrant in HR-positive, HER2 negative, BRCA1, BRCA2 or PALB2 Advanced Breast cancer.. First line therapy 

More Information
bottom of page